Itch is a major, overlooked symptom in lupus and related skin disease, review finds
☕ Includes a question for the family ↓
Skin diseasesPart of a story we are following · 8 articles · See every update
If you live with lupus or a related condition and itch is part of your day, a new review says you are not imagining how big a deal it is. Doctors and researchers have often treated itch as a side note in this kind of skin disease, and the authors are asking for that to change.
In a review of the research on four autoimmune connective tissue diseases (dermatomyositis, Sjögren’s disease, lupus erythematosus and systemic sclerosis), the authors found that itch is a dominant symptom that gets too little attention and too little study.
How the study worked
This was a systematic review, which means the authors gathered and weighed the existing research rather than testing new patients. It was published on November 20, 2026 in the J Am Acad Dermatol. Because it summarizes earlier work, it can only be as strong as the studies behind it, and the authors say that evidence on itch is scattered and hard to read.
What they found
The main point is simple: itch is common in these diseases and affects quality of life, yet the evidence on how to manage it is fragmented and opaque.
Part of the reason is how research is done. In other inflammatory skin conditions, such as atopic dermatitis, itch is often a main thing that clinical trials measure. In these four diseases it rarely is. When itch is assessed at all, it is often measured indirectly, through general disease activity scores filled out by patients.
The review also looked at what may drive itch in each disease:
- Dermatomyositis: the itch is profound. It tracks with immune messengers called IL-31 and IL-6, and with type I interferons, which are immune signaling proteins.
- Sjögren’s disease: it leads to small fiber neuropathy, a problem with the body’s smallest nerve fibers. The itch involves little inflammation.
- Lupus erythematosus (skin form): itch is shaped by both type I interferons and small fiber neuropathy.
- Systemic sclerosis: it involves both type 2 inflammation and prominent small fiber neuropathy.
In other words, itch is not one thing. In some diseases it comes mostly from inflammation, in others mostly from the nerves, and in some from both. That matters, because the review looked at the cause of itch separately in each disease.
The authors also looked at the strength of evidence for possible therapies in each disease. Their conclusion is a call to action. With itch such a prominent symptom, they want a more active and dedicated approach to relieving it, guided by clinical trials that measure itch explicitly.
Why does it matter that itch is rarely measured?
If a symptom is not measured in a trial, it is hard to know whether a treatment helps it. Doctors then have little solid evidence to lean on when a patient says the itch is the worst part. Asking researchers to track itch directly is a practical step toward better answers.
What you can do today
This review does not point to a new treatment, so current advice does not change. What it does show is that itch counts as a real symptom. Jot down how itchy you feel each day, and bring that note to your next appointment so your care team can see itch in your own words.
For clinicians and researchers
Design: Systematic review of the evidence on itch in four autoimmune connective tissue diseases: dermatomyositis, Sjögren’s disease, lupus erythematosus and systemic sclerosis. The abstract gives no number of studies, n or follow-up.
Main result: Itch is described as a dominant, under-appreciated symptom. Dermatomyositis itch correlates with IL-31, IL-6 and type I interferons; Sjögren’s disease with small fiber neuropathy and pauci-inflammatory itch; CLE with type I interferons and small fiber neuropathy; SSc with type 2 inflammation and small fiber neuropathy.
Main limitation: The evidence base is fragmented: itch is rarely a trial endpoint and is inconsistently assessed, often indirectly through patient-reported disease activity scores. No pooled effect estimates are given.
Open question: Clinical trials that measure itch explicitly are needed to test therapies, with a more active and dedicated approach to relieving it in these diseases.
Talk about it at home
The scientists did not test new patients. They gathered studies that were already finished and read them side by side to see the big picture, and they noticed that itch was hardly ever measured directly. That is a bit like trying to know how fast a runner is without ever using a stopwatch.
Try it at home
Some people say an itch is only a tiny annoyance that is not worth taking seriously. Is that a myth or a fact? Think about the last time something itched so much you could not think about anything else, and decide what you would tell them.
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Cite this article
Mongevity Desk. Itch is a major, overlooked symptom in lupus and related skin disease, review finds. Mongevity. Published November 21, 2026. Accessed November 22, 2026. https://mongevity.science/skin/2026/11/itch-overlooked-lupus-autoimmune-skin-disease/Mongevity Desk. Itch is a major, overlooked symptom in lupus and related skin disease, review finds [Internet]. Mongevity; 2026 Nov 21 cited 2026 Nov 22]. Available from: https://mongevity.science/skin/2026/11/itch-overlooked-lupus-autoimmune-skin-disease/Mongevity Desk. (2026, November 21). Itch is a major, overlooked symptom in lupus and related skin disease, review finds. Mongevity. https://mongevity.science/skin/2026/11/itch-overlooked-lupus-autoimmune-skin-disease/
<a href="https://mongevity.science/skin/2026/11/itch-overlooked-lupus-autoimmune-skin-disease/">Itch is a major, overlooked symptom in lupus and related skin disease, review finds</a>
Free to share or quote with credit and a link.
Questions and answers
- Which diseases did the review cover?
- Four autoimmune connective tissue diseases: dermatomyositis, Sjögren's disease, lupus erythematosus and systemic sclerosis.
- Is itch in these diseases caused by inflammation?
- Sometimes. The review says the cause can be inflammatory, nerve-related or a mix, depending on the disease.
- Why is itch hard to study in these diseases?
- It is rarely an endpoint in clinical trials and is often measured only indirectly, through general disease activity scores.
- Does this review offer a new treatment?
- No. It maps what is known, rates the strength of evidence for possible therapies, and calls for trials that measure itch directly.





